Curaleaf Launches Florida's First Medical Cannabis Tablets

MIAMI, Sept. 12, 2019 /PRNewswire/ — Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading vertically integrated cannabis operator in the United States, announced today the company is the first in Florida to launch medical cannabis tablets, available in all 26 Curaleaf dispensaries across the state.

Curaleaf, operator of the largest cannabis retail footprint in the US, with 49 dispensaries across the country, also sells medical cannabis in tablet form in Connecticut, New Jersey, Maryland and New York, with plans to launch in additional states.

"Knowing that our premium quality medical cannabis products allow so many of our patients to live life well, we are always looking for alternative administration methods to meet patients' needs," said Joe Lusardi, Curaleaf CEO.

"We are proud to be the first to offer Florida's patients the option of medical cannabis tablets."

Joe Lusardi, Curaleaf CEO.

The tablets, which are mint-flavored, are a refreshing form of the medication that offers patients convenience, portability and ease of use as the tablet disintegrates on the tongue and is slow acting. The tablets are packaged in child-proof containers in accordance with Florida Department of Health regulations. State-certified physicians should determine which routes of administration, including tablets, are best suited to address their patients' medical conditions.

Disclaimer: past performance is not an indicator of future performance.

About Curaleaf Holdings, Inc.

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf") is the leading vertically integrated multi-state cannabis operator in the United States. It is a high-growth cannabis company with a national brand known for quality, trust and reliability. The company is positioned in highly populated, limited license states, and currently operates in 12 states with 49 dispensaries, 14 cultivation sites and 13 processing sites. Curaleaf has the executive expertise and research and development capabilities to provide leading service, selection, and accessibility across the medical and adult-use markets, as well as in the CBD category through its Curaleaf Hemp brand.

Subscribe Now
& Keep Up to Date

Get the latest pot stock recommendations, cannabis news
and industry updates straight to your inbox!

Louis O'Neill
Louis O'Neill

Louis is a writer based in Sydney with a focus on social and political issues. Having interviewed local politicians and entrepreneurs, Louis now focuses on cannabis culture, legislation & reform.

Leave a Reply

Your email address will not be published. Required fields are marked *